Scorpius Holdings, Inc. (SCPX)
USD 0.29
(-0.87%)
USD 0.29
(-0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.08 Million USD | 12.76% |
| 2022 | -39.29 Million USD | -59.86% |
| 2021 | -34.85 Million USD | -13.91% |
| 2020 | -24.59 Million USD | -17.03% |
| 2019 | -19.16 Million USD | -11.01% |
| 2018 | -17.22 Million USD | -32.67% |
| 2017 | -12.98 Million USD | 0.08% |
| 2016 | -12.29 Million USD | 37.84% |
| 2015 | -20.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.51 Million USD | 40.63% |
| 2024 Q2 | -6.86 Million USD | -177.29% |
| 2023 Q2 | -11.34 Million USD | 14.82% |
| 2023 Q3 | -8.92 Million USD | 21.3% |
| 2023 FY | - USD | 12.76% |
| 2023 Q1 | -13.31 Million USD | 6.21% |
| 2023 Q4 | -4.62 Million USD | 48.14% |
| 2022 Q2 | -9.37 Million USD | -29.02% |
| 2022 FY | - USD | -59.86% |
| 2022 Q4 | -14.19 Million USD | -20.55% |
| 2022 Q3 | -11.77 Million USD | -25.58% |
| 2022 Q1 | -7.26 Million USD | 37.39% |
| 2021 Q1 | -7.11 Million USD | 0.0% |
| 2021 FY | - USD | -13.91% |
| 2021 Q4 | -11.6 Million USD | -64.17% |
| 2021 Q3 | -7.07 Million USD | -9.58% |
| 2021 Q2 | -6.45 Million USD | 9.26% |
| 2020 FY | - USD | -17.03% |
| 2019 FY | - USD | -11.01% |
| 2018 FY | - USD | -32.67% |
| 2017 FY | - USD | 0.08% |
| 2016 FY | - USD | 37.84% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | -10.747% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 12.114% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 31.386% |
| Azitra, Inc. | -10.67 Million USD | -228.697% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -328.881% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -411.237% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | -22.666% |
| CEL-SCI Corporation | -27.56 Million USD | -27.292% |
| iBio, Inc. | -14.02 Million USD | -150.214% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -41.845% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -73.827% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | -53.702% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -152.845% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -630.885% |
| NanoViricides, Inc. | -7.75 Million USD | -352.263% |
| Oragenics, Inc. | -20.87 Million USD | -68.04% |
| BiomX Inc. | -22.81 Million USD | -53.769% |
| BiomX Inc. | -22.81 Million USD | -53.769% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 401.112% |
| Palatin Technologies, Inc. | -29.03 Million USD | -20.844% |